| Outcome Measures: |
Primary: Change in HbA1c from baseline, The change in HbA1c from baseline till end of 12 weeks in patients of type 2 diabetes mellitus, in the P2202 arms as compared to placebo., From baseline till end of 12 weeks | Secondary: Number of subjects with adverse events, Safety assessment will be done by eliciting information regarding AEs including evaluation of hypoglycemic events, physical examination, vital signs assessment, 12-lead ECGs, clinical laboratory tests, markers of HPA axis function, plasma ACTH and free testosterone, plasma rennin and serum aldosterone and self-monitoring of blood glucose profiles., From screening to 3 weeks (± 1 week) after the last visit at the end of Week 12 or early exit visit | Other: Pharmacokinetic profile (Cmax, Tmax and AUC), PK parameters derived will be maximum plasma concentration (Cmax), time at which Cmax is reached (Tmax), area under the plasma concentration curve calculated up to 24 hours (AUC 0-24h), area under the curve extrapolated to infinity (AUC 0-inf), elimination rate constant (Kel), volume of distribution (Vz), terminal elimination half life (t1/2) and protein binding., Pre dose at Day 1 Week 1 till Week 12
|
